Skip to main content
Fig. 5 | Biomaterials Research

Fig. 5

From: Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease

Fig. 5

Effects of CLB on LPS-induced protein in BV-2 cells. (A) The levels of protein and their secretion were used to measure TNF-α, IL-1β, and IL-6 levels. The relative protein levels were quantified through scanning densitometry and normalized to that of β-actin. The results are presented as the mean ± standard deviation values for each group, derived from three independent experiments. n = 6, *P < 0.05, $P < 0.01, and #P < 0.001. (B) The anti-inflammatory effects of SHAP-CLB on Aβ-induced inflammation in BV-2 cells, as determined by the expression analysis of the inflammation-related proteins IL-6, IL-1β, and TNF-α. n = 6, *P < 0.05 versus the control group, **P < 0.01 versus the control group, ***P < 0.001 versus the control group, and ###P < 0.001 versus the LPS-treated group)

Back to article page